ARA-290

ARA-290 peptide is sourced by research teams investigating the innate repair receptor — a heteromeric receptor complex distinct from the classical erythropoietin receptor — and its associated intracellular signaling cascades in controlled in vitro environments. The innate repair receptor is a tissue-protective receptor complex studied in laboratory models for its role in cellular stress response signaling, inflammatory mediator modulation, and cytoprotective pathway activation in non-haematopoietic cell systems.

ARA-290’s sequence is derived from the helix B surface of the erythropoietin molecule — a region studied for IRR engagement — and is modified to eliminate interaction with the classical erythropoietin receptor. This selectivity is the compound’s primary research utility: it allows investigators to study IRR-mediated signaling in isolation, without the confounding receptor crosstalk associated with full-length erythropoietin in cell-based assay systems.

Research applications include IRR binding affinity characterisation, inflammatory cytokine pathway modulation studies in cell culture models, cytoprotective signaling cascade investigation in metabolic and neuronal cell systems, and comparative receptor selectivity profiling across erythropoietin receptor family members.

ARA-290 peptide is investigated in research environments for its selective engagement of the innate repair receptor in non-haematopoietic cell model platforms. It is studied within controlled laboratory models examining downstream signaling pathway responses, including JAK2 activation — Janus kinase 2 is an intracellular enzyme that initiates a signaling cascade following receptor engagement — and STAT transcription factor phosphorylation. Phosphorylation is a molecular modification that activates or deactivates proteins by attaching a phosphate group; it is a primary readout in kinase signaling pathway research.

The compound is explored for experimental peptide research involving inflammatory mediator suppression in in vitro systems, where investigators examine how IRR activation influences cytokine expression profiles — the pattern of inflammatory signaling proteins produced by stimulated cells — under defined experimental conditions. Its receptor selectivity profile also makes it applicable to comparative receptor pharmacology studies examining the structural determinants of erythropoietin receptor family member differentiation.

ARA-290 peptide is supplied as a lyophilised powder. Lyophilisation is a freeze-drying process that stabilises the compound in solid form for laboratory storage and maintains peptide integrity prior to experimental use.

Recommended handling conditions:

• Store in a cool, dry environment away from direct light
• Keep sealed until use within a validated laboratory setting
• Protect from moisture and heat exposure at all storage stages
• Reconstitution — dissolving the compound in a suitable laboratory-grade solvent — must be performed by qualified research personnel within an institutional laboratory environment
• Following reconstitution, store under conditions specified in the accompanying analytical documentation
• Handle exclusively within regulated research facilities in compliance with applicable institutional review standards

This compound is not intended for use outside approved laboratory environments.

Each unit of ARA-290 peptide undergoes quality control testing prior to dispatch. Peptide purity is verified through liquid chromatography-mass spectrometry (LC-MS), confirming compound concentration and the absence of significant impurities. Mass spectrometry is applied to validate the eleven-amino acid sequence and confirm the integrity of residue modifications at receptor selectivity-determining positions.

Batch-to-batch consistency is maintained through internal quality assurance standards across all production runs. Each pack size is accompanied by analytical documentation providing peptide purity data, sequence confirmation, and batch identifiers. This supports reproducible research peptide supply to institutions and laboratories in the United States and internationally, and meets the documentation requirements of structured receptor signaling research programme

• CAS: 1208243-50-8
• Chemical Formula: C₅₁H₈₄N₁₆O₂₁
• Molecular Weight: 1257.3 g/mol
• Peptide Sequence: XEQLERALNSS
• Synonyms: Cibinetide, PHBSP
• Shelf life: 24 months from the manufacturing date.

ARA-290 is a chemically synthesized eleven-amino acid peptide corresponding to a modified sequence derived from the helix B surface region of erythropoietin — a naturally occurring signaling protein. Its sequence incorporates specific residue modifications that preserve IRR binding affinity while eliminating engagement of the classical erythropoietin receptor homodimer. A homodimer is a receptor complex formed from two identical protein subunits; the classical erythropoietin receptor assembles in this configuration, while the innate repair receptor incorporates a different subunit combination.

This receptor selectivity is achieved through targeted amino acid substitutions at positions that determine classical receptor contact geometry. The resulting compound binds the IRR complex while remaining pharmacologically inert at the classical receptor — a property that is itself a subject of investigation in comparative receptor binding and structure-activity relationship research.

Helix B surface peptides are studied in laboratory research because they represent a class of receptor-selective molecular tools that allow investigators to dissect signaling pathway contributions within complex receptor family systems with greater precision than full-length protein ligands permit.

• Eleven-amino acid helix B surface peptide (HBSP) analogue engineered to engage the innate repair receptor without activating the classical erythropoietin receptor — a receptor selectivity distinction that makes it a precise molecular tool for isolating IRR-mediated signaling in cell-based research models
• 14mg pack size suited to multi-assay laboratory programmes examining IRR pathway activation across multiple experimental conditions or cell line platforms within a single research cycle
• High-purity compound, batch-tested and verified through LC-MS prior to dispatch
• Secure packaging and discreet shipment as standard for institutional and laboratory procurement